Proteasome inhibitor-induced modulation reveals the spliceosome as a specific therapeutic vulnerability in multiple myeloma

Proteasome inhibitor-induced modulation reveals the spliceosome as a specific therapeutic vulnerability in multiple myeloma

The mechanisms of action of proteasome inhibitors (PI) in multiple myeloma (MM) treatment are not fully elucidated. Here, the authors use unbiased phosphoproteomics in PI-treated MM and show increased phosphorylation of splicing-associated proteins, ultimately revealing splicing interference as a mo...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Hector H. Huang, Ian D. Ferguson, Alexis M. Thornton, Prabhakar Bastola, Christine Lam, Yu-Hsiu T. Lin, Priya Choudhry, Margarette C. Mariano, Makeba D. Marcoulis, Chin Fen Teo, Julia Malato, Paul J. Phojanakong, Thomas G. Martin, Jeffrey L. Wolf, Sandy W. Wong, Nina Shah, Byron Hann, Angela N. Brooks, Arun P. Wiita
Formato: article
Lenguaje:EN
Publicado: Nature Portfolio 2020
Materias:
Science
Q
Acceso en línea:https://doaj.org/article/9ede6677994c4ad081bb8e902cda0b7a
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
Descripción
Sumario:The mechanisms of action of proteasome inhibitors (PI) in multiple myeloma (MM) treatment are not fully elucidated. Here, the authors use unbiased phosphoproteomics in PI-treated MM and show increased phosphorylation of splicing-associated proteins, ultimately revealing splicing interference as a mode of PI action as well as demonstrating the spliceosome as a specific therapeutic vulnerability in this disease.

Ejemplares similares